{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T00:13:16Z","timestamp":1792800796986,"version":"4.5.0"},"reference-count":140,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,26]],"date-time":"2026-05-26T00:00:00Z","timestamp":1779753600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Critical Reviews in Oncology\/Hematology"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.critrevonc.2026.105382","type":"journal-article","created":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T06:55:00Z","timestamp":1779173700000},"page":"105382","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Immune checkpoint inhibitor resistance in non-small cell lung cancer: An updated view through the cancer-immunity cycle"],"prefix":"10.1016","volume":"225","author":[{"given":"Qinying","family":"Sun","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinrui","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingyue","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuchao","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.critrevonc.2026.105382_bib1","first-page":"749","article-title":"Folated-nanocarrier for paclitaxel drug delivery in leukemia cancer therapy","volume":"10","author":"Al-Musawi","year":"2018","journal-title":"J. Pharm. Sci. Res."},{"key":"10.1016\/j.critrevonc.2026.105382_bib2","doi-asserted-by":"crossref","DOI":"10.1063\/5.0092330","article-title":"Nanoformulation of intelligence polymeric nanocarrier for resveratrol targeted delivery and study its cytotoxic, apoptotic, and genetics effects in epidermoid carcinoma therapy","volume":"2437","author":"Alnasraui","year":"2022","journal-title":"AIP Conf. Proc."},{"key":"10.1016\/j.critrevonc.2026.105382_bib3","doi-asserted-by":"crossref","first-page":"3278","DOI":"10.1158\/1538-7445.AM2022-3278","article-title":"Abstract 3278: Identification of epigenetic therapy induced tumor antigens to promote proliferation and infiltration of antigen specific T cells in non-small cell lung cancer","volume":"82","author":"An","year":"2022","journal-title":"Cancer Res."},{"key":"10.1016\/j.critrevonc.2026.105382_bib4","doi-asserted-by":"crossref","first-page":"NG01","DOI":"10.1158\/1538-7445.AM2017-NG01","article-title":"Abstract NG01: Evolution of neoantigen landscape during immune checkpoint blockade in non-small cell lung cancer","volume":"77","author":"Anagnostou","year":"2017","journal-title":"Cancer Res."},{"key":"10.1016\/j.critrevonc.2026.105382_bib5","doi-asserted-by":"crossref","DOI":"10.3390\/cells10123323","article-title":"Post-Translational Modification of HMGB1 Disulfide Bonds in Stimulating and Inhibiting Inflammation","volume":"10","author":"Andersson","year":"2021","journal-title":"Cells"},{"key":"10.1016\/j.critrevonc.2026.105382_bib6","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/s12967-024-06023-8","article-title":"PD-L1 and IFN-\u03b3 modulate Non-Small Cell Lung Cancer (NSCLC) cell plasticity associated to immune checkpoint inhibitor (ICI)-mediated hyperprogressive disease (HPD)","volume":"23","author":"Angelicola","year":"2025","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.critrevonc.2026.105382_bib7","doi-asserted-by":"crossref","first-page":"2872","DOI":"10.1200\/JCO.2018.79.0006","article-title":"Impact of baseline steroids on efficacy of programmed cell death-1 and programmed death-ligand 1 blockade in patients with non-small-cell lung cancer","volume":"36","author":"Arbour","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105382_bib8","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.lungcan.2021.02.035","article-title":"Strategies to overcome resistance to immune checkpoint blockade in lung cancer","volume":"154","author":"Attili","year":"2021","journal-title":"Lung Cancer"},{"key":"10.1016\/j.critrevonc.2026.105382_bib9","doi-asserted-by":"crossref","DOI":"10.1016\/j.tranon.2019.12.010","article-title":"Resistance to Checkpoint Inhibition in Cancer Immunotherapy","volume":"13","author":"Barrueto","year":"2020","journal-title":"Transl. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105382_bib10","doi-asserted-by":"crossref","DOI":"10.1016\/j.tranon.2022.101555","article-title":"The thin red line between the immune system and cancer evolution","volume":"27","author":"Baxevanis","year":"2023","journal-title":"Transl. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105382_bib11","doi-asserted-by":"crossref","first-page":"2024","DOI":"10.3389\/fimmu.2024.1384121","article-title":"Further knowledge and developments in resistance mechanisms to immune checkpoint inhibitors","volume":"15","author":"Berland","year":"2024","journal-title":"Front. Immunol."},{"key":"10.1016\/j.critrevonc.2026.105382_bib12","doi-asserted-by":"crossref","DOI":"10.18632\/oncotarget.809","article-title":"Coordinate PI3K pathway and Bcl-2 family disruption in AML","volume":"3","author":"Bose","year":"2012","journal-title":"Oncotarget"},{"key":"10.1016\/j.critrevonc.2026.105382_bib13","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.4049\/jimmunol.178.3.1505","article-title":"Effects of vascular endothelial growth factor on the lymphocyte-endothelium interactions: identification of Caveolin-1 and nitric oxide as control points of endothelial cell anergy1","volume":"178","author":"Bouzin","year":"2007","journal-title":"J. Immunol."},{"key":"10.1016\/j.critrevonc.2026.105382_bib14","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.molimm.2022.05.060","article-title":"Cross presentation: more exotic pathwaysEpigenetic repression of MHC class I antigen presentation enables immune evasion in cancer","volume":"150","author":"Burr","year":"2022","journal-title":"Mol. Immunol."},{"key":"10.1016\/j.critrevonc.2026.105382_bib15","doi-asserted-by":"crossref","DOI":"10.1002\/cam4.70254","article-title":"Do corticosteroids affect immunotherapy efficacy in malignancy? - A systematic review","volume":"13","author":"Byron","year":"2024","journal-title":"Cancer Med."},{"key":"10.1016\/j.critrevonc.2026.105382_bib16","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1158\/1538-7445.AM2024-164","article-title":"Abstract 164: Genetic elimination of \u03b2-catenin using a doxycycline-regulated GEM model fails to restore checkpoint blockade efficacy due to persistent M2-like macrophages","volume":"84","author":"Cabanov","year":"2024","journal-title":"Cancer Res."},{"key":"10.1016\/j.critrevonc.2026.105382_bib17","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.4049\/jimmunol.2300046","article-title":"Tumor Suppressor Adenomatous Polyposis Coli Sustains Dendritic Cell Tolerance through IL-10 in a \u03b2-Catenin\u2013Dependent Manner","volume":"210","author":"Cao","year":"2023","journal-title":"J. Immunol."},{"key":"10.1016\/j.critrevonc.2026.105382_bib18","first-page":"2024","article-title":"Revealing the mechanism of natural product-induced immunogenic cell death: opening a new chapter in tumor immunotherapy","volume":"15","author":"Chen","year":"2024","journal-title":"Front. Immunol."},{"key":"10.1016\/j.critrevonc.2026.105382_bib19","doi-asserted-by":"crossref","first-page":"2924","DOI":"10.3390\/cancers13122924","article-title":"Classification oF Non-small Cell Lung Cancer\u2019s tumor immune micro-environment and strategies to augment its response to immune checkpoint blockade","volume":"13","author":"Chi","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.critrevonc.2026.105382_bib20","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1111\/cas.13194","article-title":"Suppressors of cytokine signaling: Potential immune checkpoint molecules for cancer immunotherapy","volume":"108","author":"Chikuma","year":"2017","journal-title":"Cancer Sci."},{"key":"10.1016\/j.critrevonc.2026.105382_bib21","doi-asserted-by":"crossref","first-page":"20327","DOI":"10.1073\/pnas.0808036105","article-title":"Mechanism of apoptosis induction by inhibition of the anti-apoptotic BCL-2 proteins","volume":"105","author":"Chipuk","year":"2008","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.critrevonc.2026.105382_bib22","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1038\/s41571-022-00689-z","article-title":"Clinical implications of T cell exhaustion for cancer immunotherapy","volume":"19","author":"Chow","year":"2022","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105382_bib23","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-001403","article-title":"Baseline BMI and BMI variation during first line pembrolizumab in NSCLC patients with a PD-L1 expression \u2265 50%: a multicenter study with external validation","volume":"8","author":"Cortellini","year":"2020","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.critrevonc.2026.105382_bib24","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-004374","article-title":"Prognostic effect of body mass index in patients with advanced NSCLC treated with chemoimmunotherapy combinations","volume":"10","author":"Cortellini","year":"2022","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.critrevonc.2026.105382_bib25","doi-asserted-by":"crossref","first-page":"2623","DOI":"10.1200\/JCO.2023.41.16_suppl.2623","article-title":"Role of HLA class-I antigen peptide loading complex components in immune evasion and treatment sensitivity in human lung cancer","volume":"41","author":"Costantini","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105382_bib26","doi-asserted-by":"crossref","first-page":"2168","DOI":"10.1038\/s41467-020-16079-x","article-title":"Systemic short chain fatty acids limit antitumor effect of CTLA-4 blockade in hosts with cancer","volume":"11","author":"Coutzac","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.critrevonc.2026.105382_bib27","article-title":"Subclonal landscape of cancer drives resistance to immune therapy","volume":"30","author":"Craig","year":"2022","journal-title":"Cancer Treat. Res. Commun."},{"key":"10.1016\/j.critrevonc.2026.105382_bib28","doi-asserted-by":"crossref","DOI":"10.1016\/j.lungcan.2024.107855","article-title":"Immune checkpoint inhibition in early-stage non-small cell lung cancer","volume":"193","author":"Cuppens","year":"2024","journal-title":"Lung Cancer"},{"key":"10.1016\/j.critrevonc.2026.105382_bib29","doi-asserted-by":"crossref","first-page":"2194","DOI":"10.3390\/cancers17132194","article-title":"Real-World Data on Immune-Checkpoint Inhibitors in Elderly Patients with Advanced Non-Small Cell Lung Cancer: A Retrospective Study","volume":"17","author":"del Corral-Morales","year":"2025","journal-title":"Cancers"},{"key":"10.1016\/j.critrevonc.2026.105382_bib30","doi-asserted-by":"crossref","first-page":"7176","DOI":"10.1158\/0008-5472.CAN-11-1301","article-title":"Egfl7 Promotes Tumor Escape from Immunity by Repressing Endothelial Cell Activation","volume":"71","author":"Delfortrie","year":"2011","journal-title":"Cancer Res."},{"key":"10.1016\/j.critrevonc.2026.105382_bib31","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1093\/annonc\/mdy103","article-title":"Negative association of antibiotics on clinical activity of immune checkpoint inhibitors in patients with advanced renal cell and non-small-cell lung cancer","volume":"29","author":"Derosa","year":"2018","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105382_bib32","doi-asserted-by":"crossref","first-page":"9037","DOI":"10.1200\/JCO.2023.41.16_suppl.9037","article-title":"Exploring the potential of combination immune checkpoint strategies in non-small cell lung cancer (NSCLC)","volume":"41","author":"Desai","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105382_bib33","doi-asserted-by":"crossref","first-page":"5525","DOI":"10.1158\/1538-7445.AM2020-5525","article-title":"Abstract 5525: VISTA\/PSGL1 axis as a dominant immunomodulatory pathway in human non-small cell lung cancer","volume":"80","author":"Ding","year":"2020","journal-title":"Cancer Res."},{"key":"10.1016\/j.critrevonc.2026.105382_bib34","doi-asserted-by":"crossref","DOI":"10.1002\/smtd.202300354","article-title":"Advances in Immunogenic Cell Death for Cancer Immunotherapy","volume":"7","author":"Ding","year":"2023","journal-title":"Small Methods"},{"key":"10.1016\/j.critrevonc.2026.105382_bib35","doi-asserted-by":"crossref","DOI":"10.1016\/j.lungcan.2024.107925","article-title":"Age-related efficacy of immunotherapies in advanced non-small cell lung cancer: a comprehensive meta-analysis","volume":"195","author":"Ding","year":"2024","journal-title":"Lung Cancer"},{"key":"10.1016\/j.critrevonc.2026.105382_bib36","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1186\/s12964-020-00653-3","article-title":"Lactate-induced MRP1 expression contributes to metabolism-based etoposide resistance in non-small cell lung cancer cells","volume":"18","author":"Dong","year":"2020","journal-title":"Cell Commun. Signal."},{"key":"10.1016\/j.critrevonc.2026.105382_bib37","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1038\/s41698-024-00630-w","article-title":"Antibiotics are associated with worse outcomes in lung cancer patients treated with chemotherapy and immunotherapy","volume":"8","author":"Elkrief","year":"2024","journal-title":"npj Precis. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105382_bib38","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1038\/s42255-020-00280-9","article-title":"Metabolic and epigenetic regulation of T-cell exhaustion","volume":"2","author":"Franco","year":"2020","journal-title":"Nat. Metab."},{"key":"10.1016\/j.critrevonc.2026.105382_bib39","doi-asserted-by":"crossref","DOI":"10.1158\/1538-7445.AM2025-4852","article-title":"Abstract 4852: Carbonic anhydrase IX and hypoxia-induced metabolic adaptations in tumor immune microenvironment: Insights into enhancing anti-PD1 efficacy in lung cancer","author":"Fusco","year":"2025","journal-title":"Cancer Res."},{"key":"10.1016\/j.critrevonc.2026.105382_bib40","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1158\/2159-8290.CD-17-0593","article-title":"Impaired HLA Class I Antigen Processing and Presentation as a Mechanism of Acquired Resistance to Immune Checkpoint Inhibitors in Lung Cancer","volume":"7","author":"Gettinger","year":"2017","journal-title":"Cancer Discov."},{"key":"10.1016\/j.critrevonc.2026.105382_bib41","doi-asserted-by":"crossref","first-page":"1986","DOI":"10.1016\/S0140-6736(24)00792-X","article-title":"Immunotherapy in frail non-small-cell lung cancer patients","volume":"403","author":"Gijtenbeek","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.critrevonc.2026.105382_bib42","doi-asserted-by":"crossref","first-page":"6731","DOI":"10.1038\/s41467-023-42417-w","article-title":"DNMT and HDAC inhibition induces immunogenic neoantigens from human endogenous retroviral element-derived transcripts","volume":"14","author":"Goyal","year":"2023","journal-title":"Nat. Commun."},{"key":"10.1016\/j.critrevonc.2026.105382_bib43","article-title":"Analysis of PD1, LAG3, TIGIT, and TIM3 expression in human lung adenocarcinoma reveals a 25-gene signature predicting immunotherapy response","volume":"5","author":"Gu\u00e9gan","year":"2024","journal-title":"Cell Rep. Med."},{"key":"10.1016\/j.critrevonc.2026.105382_bib44","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1200\/JCO.2024.42.23_suppl.209","article-title":"Effect of heterozygosity loss of HLA-I on immune evasion and promotion of non-small cell lung cancer brain metastasis and immunotherapy resistance","volume":"42","author":"Han","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105382_bib45","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2024-011427","article-title":"Decoding resistance to immune checkpoint inhibitors in non-small cell lung cancer: a comprehensive analysis of plasma proteomics and therapeutic implications","volume":"13","author":"Harel","year":"2025","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.critrevonc.2026.105382_bib46","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1158\/1078-0432.CCR-19-1868","article-title":"Macrophage-Derived CXCL9 and CXCL10 Are Required for Antitumor Immune Responses Following Immune Checkpoint Blockade","volume":"26","author":"House","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.critrevonc.2026.105382_bib47","first-page":"9","article-title":"Extracellular HMGB1 blockade inhibits tumor growth through profoundly remodeling immune microenvironment and enhances checkpoint inhibitor-based immunotherapy","author":"Hubert","year":"2021","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.critrevonc.2026.105382_bib48","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1248\/bpb.b23-00713","article-title":"Immune Checkpoint Inhibitor Is Associated with Improved Survival in Advanced Non-small Cell Lung Cancer Occurring in Patients with Autoimmune Disease","volume":"47","author":"Ihara","year":"2024","journal-title":"Biol. & Pharm. Bull."},{"key":"10.1016\/j.critrevonc.2026.105382_bib49","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1002\/1878-0261.12937","article-title":"Cancer-associated fibroblast migration in non-small cell lung cancers is modulated by increased integrin \u03b111 expression","volume":"15","author":"Iwai","year":"2021","journal-title":"Mol. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105382_bib50","doi-asserted-by":"crossref","first-page":"7013","DOI":"10.3390\/ijms25137013","article-title":"The Role of Aging and Senescence in Immune Checkpoint Inhibitor Response and Toxicity","volume":"25","author":"Jain","year":"2024","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.critrevonc.2026.105382_bib51","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1111\/imr.13301","article-title":"Decoding immunogenic cell death from a dendritic cell perspective","volume":"321","author":"Janssens","year":"2024","journal-title":"Immunol. Rev."},{"key":"10.1016\/j.critrevonc.2026.105382_bib52","article-title":"Gene signature of antigen processing and presentation machinery predicts response to checkpoint blockade in non-small cell lung cancer (NSCLC) and melanoma","volume":"8","author":"Jeffrey","year":"2020","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.critrevonc.2026.105382_bib53","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1038\/bjc.2017.434","article-title":"Mechanisms of resistance to immune checkpoint inhibitors","volume":"118","author":"Jenkins","year":"2018","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.critrevonc.2026.105382_bib54","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1186\/s13046-021-02133-z","article-title":"Serological assessment of collagen fragments and tumor fibrosis may guide immune checkpoint inhibitor therapy","volume":"40","author":"Jensen","year":"2021","journal-title":"J. Exp. & Clin. Cancer Res."},{"key":"10.1016\/j.critrevonc.2026.105382_bib55","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1038\/s41568-021-00339-z","article-title":"Antigen presentation in cancer: insights into tumour immunogenicity and immune evasion","volume":"21","author":"Jhunjhunwala","year":"2021","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.critrevonc.2026.105382_bib56","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.3389\/fimmu.2020.622509","article-title":"Exhausted CD8+T Cells in the Tumor Immune Microenvironment: New Pathways to Therapy","volume":"11","author":"Jiang","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.critrevonc.2026.105382_bib57","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1186\/s40364-020-00228-x","article-title":"Roles of IFN-\u03b3 in tumor progression and regression: a review","volume":"8","author":"Jorgovanovic","year":"2020","journal-title":"Biomark. Res."},{"key":"10.1016\/j.critrevonc.2026.105382_bib58","doi-asserted-by":"crossref","first-page":"2577","DOI":"10.1158\/1535-7163.MCT-21-0201","article-title":"Characterization of KRAS Mutation Subtypes in Non\u2013small Cell Lung Cancer","volume":"20","author":"Judd","year":"2021","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.critrevonc.2026.105382_bib59","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1038\/s41577-019-0218-4","article-title":"Tumour-intrinsic resistance to immune checkpoint blockade","volume":"20","author":"Kalbasi","year":"2020","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.critrevonc.2026.105382_bib60","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1002\/jlb.61.2.179","article-title":"Endothelial P-selectin and VCAM-1 each can function as primary adhesive mechanisms for T cells under conditions of flow","volume":"61","author":"Konstantopoulos","year":"1997","journal-title":"J. Leukoc. Biol."},{"key":"10.1016\/j.critrevonc.2026.105382_bib61","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1007\/s00262-022-03255-9","article-title":"A Fc-VEGF chimeric fusion enhances PD-L1 immunotherapy via inducing immune reprogramming and infiltration in the immunosuppressive tumor microenvironment","volume":"72","author":"Kuo","year":"2023","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.critrevonc.2026.105382_bib62","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1007\/s00281-019-00744-5","article-title":"CD8+ T cell exhaustion","volume":"41","author":"Kurachi","year":"2019","journal-title":"Semin. Immunopathol."},{"key":"10.1016\/j.critrevonc.2026.105382_bib63","doi-asserted-by":"crossref","first-page":"1818","DOI":"10.3390\/cancers16101818","article-title":"LKB1 Loss Correlates with STING Loss and, in Cooperation with \u03b2-Catenin Membranous Loss, Indicates Poor Prognosis in Patients with Operable Non-Small Cell Lung Cancer","volume":"16","author":"Lagoudaki","year":"2024","journal-title":"Cancers"},{"key":"10.1016\/j.critrevonc.2026.105382_bib64","doi-asserted-by":"crossref","first-page":"9025","DOI":"10.1200\/JCO.2021.39.15_suppl.9025","article-title":"Anti PD-(L)1 in KRAS mutant advanced nsclcs: A meta-analysis of randomized controlled trials","volume":"39","author":"Landre","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105382_bib65","doi-asserted-by":"crossref","first-page":"2649","DOI":"10.1158\/1538-7445.AM2024-2649","article-title":"Abstract 2649: A new role for the aryl hydrocarbon receptor (AhR) as a proximal mediator of immune checkpoints (PD-L1\/2 and IDO1) in non-small cell lung cancer: Insights into an interferon-induced, LncRNA-and JAK\/STAT-mediated signaling pathway","volume":"84","author":"Lara","year":"2024","journal-title":"Cancer Res."},{"key":"10.1016\/j.critrevonc.2026.105382_bib66","doi-asserted-by":"crossref","first-page":"5080","DOI":"10.1158\/1538-7445.AM2023-5080","article-title":"Abstract 5080: TU2218, a novel ALK5\/VEGFR2 dual inhibitor, overcomes tumor endothelial cell anergy and enhances anti-PD1 immunotherapy efficacy","volume":"83","author":"Lee","year":"2023","journal-title":"Cancer Res."},{"key":"10.1016\/j.critrevonc.2026.105382_bib67","article-title":"AXL targeting restores PD-1 blockade sensitivity of STK11\/LKB1 mutant NSCLC through expansion of TCF1+ CD8 T cells","volume":"3","author":"Li","year":"2022","journal-title":"Cell Rep. Med."},{"key":"10.1016\/j.critrevonc.2026.105382_bib68","doi-asserted-by":"crossref","first-page":"2021","DOI":"10.3389\/fimmu.2021.749461","article-title":"Characterization of Somatic Mutations That Affect Neoantigens in Non-Small Cell Lung Cancer","volume":"12","author":"Liang","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.critrevonc.2026.105382_bib69","doi-asserted-by":"crossref","DOI":"10.1096\/fj.202403019R","article-title":"Metabolic Reprogramming of Glycolysis, Lipids, and Amino Acids in Tumors: Impact on CD8+ T Cell Function and Targeted Therapeutic Strategies","volume":"39","author":"Liang","year":"2025","journal-title":"FASEB J."},{"key":"10.1016\/j.critrevonc.2026.105382_bib70","article-title":"CXCL9\/10-engineered dendritic cells promote T cell activation and enhance immune checkpoint blockade for lung cancer","volume":"5","author":"Lim","year":"2024","journal-title":"Cell Rep. Med."},{"key":"10.1016\/j.critrevonc.2026.105382_bib71","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1038\/s43018-022-00433-7","article-title":"Single-cell meta-analyses reveal responses of tumor-reactive CXCL13+ T cells to immune-checkpoint blockade","volume":"3","author":"Liu","year":"2022","journal-title":"Nat. Cancer"},{"key":"10.1016\/j.critrevonc.2026.105382_bib72","doi-asserted-by":"crossref","first-page":"L65","DOI":"10.1152\/ajplung.00421.2020","article-title":"Lung immune tone via gut-lung axis: gut-derived LPS and short-chain fatty acids\u2019 immunometabolic regulation of lung IL-1\u03b2, FFAR2, and FFAR3 expression","volume":"321","author":"Liu","year":"2021","journal-title":"Am. J. Physiol. -Lung Cell. Mol. Physiol."},{"key":"10.1016\/j.critrevonc.2026.105382_bib73","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.7150\/ijbs.104079","article-title":"Revisiting of Cancer Immunotherapy: Insight from the Dialogue between Glycolysis and PD-1\/PD-L1 Axis in the Tumor Microenvironment","volume":"21","author":"Liu","year":"2025","journal-title":"Int. J. Biol. Sci."},{"key":"10.1016\/j.critrevonc.2026.105382_bib74","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1248\/bpb.33.752","article-title":"Ferulic Acid Attenuates Adhesion Molecule Expression in Gamma-Radiated Human Umbilical Vascular Endothelial Cells","volume":"33","author":"Ma","year":"2010","journal-title":"Biol. Pharm. Bull."},{"key":"10.1016\/j.critrevonc.2026.105382_bib75","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1126\/science.abc3421","article-title":"Microbiome-derived inosine modulates response to checkpoint inhibitor immunotherapy","volume":"369","author":"Mager","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.critrevonc.2026.105382_bib76","article-title":"Neoantigen architectures define immunogenicity and drive immune evasion of tumors with heterogenous neoantigen expression","volume":"12","author":"Malte","year":"2024","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.critrevonc.2026.105382_bib77","doi-asserted-by":"crossref","first-page":"A043","DOI":"10.1158\/2326-6074.TUMIMM23-A043","article-title":"Abstract A043: Identifying critical vulnerabilities that sensitise Lkb1-mutant lung adenocarcinoma to T cell mediated killing","volume":"11","author":"McDonald","year":"2023","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.critrevonc.2026.105382_bib78","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1016\/j.cell.2017.10.001","article-title":"Allele-Specific HLA Loss and Immune Escape in Lung Cancer Evolution","volume":"171","author":"McGranahan","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.critrevonc.2026.105382_bib79","doi-asserted-by":"crossref","first-page":"LB-A03","DOI":"10.1158\/1535-7163.TARG-17-LB-A03","article-title":"Abstract LB-A03: Allele specific HLA loss and immune escape in lung cancer evolution","volume":"17","author":"McGranahan","year":"2018","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.critrevonc.2026.105382_bib80","doi-asserted-by":"crossref","first-page":"E2776","DOI":"10.1073\/pnas.1620498114","article-title":"Exhaustion-associated regulatory regions in CD8+ tumor-infiltrating T cells","volume":"114","author":"Mognol","year":"2017","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.critrevonc.2026.105382_bib81","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1158\/2159-8290.CD-20-0672","article-title":"Somatic HLA Class I Loss Is a Widespread Mechanism of Immune Evasion Which Refines the Use of Tumor Mutational Burden as a Biomarker of Checkpoint Inhibitor Response","volume":"11","author":"Montesion","year":"2021","journal-title":"Cancer Discov."},{"key":"10.1016\/j.critrevonc.2026.105382_bib82","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1210\/clinem\/dgae667","article-title":"Wnt\/B-catenin Activation and TP53 Mutations Associate With Distinct Immune Profiles in Advanced Thyroid Cancer","volume":"110","author":"Moretti","year":"2025","journal-title":"J. Clin. Endocrinol. & Metab."},{"key":"10.1016\/j.critrevonc.2026.105382_bib83","doi-asserted-by":"crossref","first-page":"8022","DOI":"10.1073\/pnas.1918971117","article-title":"Sufficiency of CD40 activation and immune checkpoint blockade for T cell priming and tumor immunity","volume":"117","author":"Morrison","year":"2020","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.critrevonc.2026.105382_bib84","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1016\/j.jtho.2022.04.009","article-title":"Discovery of Biomarkers of Resistance to Immune Checkpoint Blockade in NSCLC Using High-Plex Digital Spatial Profiling","volume":"17","author":"Moutafi","year":"2022","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105382_bib85","doi-asserted-by":"crossref","first-page":"203","DOI":"10.3892\/ol.2021.12464","article-title":"Tumor \u03b2\u2011catenin expression is associated with immune evasion in non\u2011small cell lung cancer with high tumor mutation burden","volume":"21","author":"Muto","year":"2021","journal-title":"Oncol. Lett."},{"key":"10.1016\/j.critrevonc.2026.105382_bib86","doi-asserted-by":"crossref","first-page":"3303","DOI":"10.1111\/cas.15497","article-title":"Mechanisms of resistance to immune checkpoint inhibitors","volume":"113","author":"Nagasaki","year":"2022","journal-title":"Cancer Sci."},{"key":"10.1016\/j.critrevonc.2026.105382_bib87","doi-asserted-by":"crossref","DOI":"10.1177\/10732748241285474","article-title":"Predictability of Neutrophile to Lymphocyte Ratio and Platelet to Lymphocyte Ratio on the Effectiveness of Immune Checkpoint Inhibitors in Non-small Cell Lung Cancer patients: A Meta-Analysis","volume":"31","author":"Nguyen","year":"2024","journal-title":"Cancer Control"},{"key":"10.1016\/j.critrevonc.2026.105382_bib88","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.85263","article-title":"Decoupled neoantigen cross-presentation by dendritic cells limits anti-tumor immunity against tumors with heterogeneous neoantigen expression","volume":"12","author":"Nguyen","year":"2023","journal-title":"eLife"},{"key":"10.1016\/j.critrevonc.2026.105382_bib89","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1158\/1538-7445.AM2022-1370","article-title":"Abstract 1370: Targeting LSD1 rescues MHC-I antigen presentation in small cell lung cancer","volume":"82","author":"Nguyen","year":"2022","journal-title":"Cancer Res."},{"key":"10.1016\/j.critrevonc.2026.105382_bib90","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1158\/1538-7445.AM2025-923","article-title":"Abstract 923: The role of NNMT in anti-tumor immunity in LKB1 deficient NSCLCs","volume":"85","author":"Nguyen","year":"2025","journal-title":"Cancer Res."},{"key":"10.1016\/j.critrevonc.2026.105382_bib91","doi-asserted-by":"crossref","first-page":"5088","DOI":"10.1158\/1538-7445.AM2024-5088","article-title":"Abstract 5088: Evaluating TNF-receptor associated factor 2 (TRAF2) as a targetable driver of immune resistance in LKB1 deficient non-small cell lung cancer","volume":"84","author":"Nourmohammadi","year":"2024","journal-title":"Cancer Res."},{"key":"10.1016\/j.critrevonc.2026.105382_bib92","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1007\/s10456-022-09863-4","article-title":"Proinflammatory activity of VEGF-targeted treatment through reversal of tumor endothelial cell anergy","volume":"26","author":"Nowak-Sliwinska","year":"2023","journal-title":"Angiogenesis"},{"key":"10.1016\/j.critrevonc.2026.105382_bib93","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.atherosclerosis.2022.05.015","article-title":"Cholesterol crystals drive metabolic reprogramming and M1 macrophage polarisation in primary human macrophages","volume":"352","author":"O'Rourke","year":"2022","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.critrevonc.2026.105382_bib94","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1046\/j.1365-2567.2000.00980.x","article-title":"Interferon-\u03b3 up-regulates intercellular adhesion molecule-1 and vascular cell adhesion molecule-1 and recruits lymphocytes into the vagina of immune mice challenged with herpes simplex virus-2","volume":"99","author":"Parr","year":"2000","journal-title":"Immunology"},{"key":"10.1016\/j.critrevonc.2026.105382_bib95","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2019.172487","article-title":"Enlightening the role of high mobility group box 1 (HMGB1) in inflammation: Updates on receptor signalling","author":"Paudel","year":"2019","journal-title":"Eur. J. Pharmacol."},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105382_bib96","doi-asserted-by":"crossref","DOI":"10.18632\/oncotarget.23469","article-title":"HLA class I loss and PD-L1 expression in lung cancer: impact on T-cell infiltration and immune escape","volume":"9","author":"Perea","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.critrevonc.2026.105382_bib97","doi-asserted-by":"crossref","first-page":"6767","DOI":"10.1158\/1538-7445.AM2023-6767","article-title":"Abstract 6767: Cancer-associated fibroblasts promote T-cell exclusion and resistance to immunotherapy in non-small cell lung cancer with tertiary lymphoid structures","volume":"83","author":"Peyraud","year":"2023","journal-title":"Cancer Res."},{"key":"10.1016\/j.critrevonc.2026.105382_bib98","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1016\/j.immuni.2016.06.001","article-title":"Resistance Mechanisms to Immune-Checkpoint Blockade in Cancer: Tumor-Intrinsic and -Extrinsic Factors","volume":"44","author":"Pitt","year":"2016","journal-title":"Immunity"},{"key":"10.1016\/j.critrevonc.2026.105382_bib99","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1158\/1538-7445.AM2024-1201","article-title":"Abstract 1201: Pervasive HLA disruption fuels cancer evolution","volume":"84","author":"Puttick","year":"2024","journal-title":"Cancer Res."},{"key":"10.1016\/j.critrevonc.2026.105382_bib100","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1186\/s12943-025-02276-z","article-title":"IL-4 mediated TAP2 downregulation is a dominant and reversible mechanism of immune evasion and immunotherapy resistance in non-small cell lung cancer","volume":"24","author":"Ranjan","year":"2025","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.critrevonc.2026.105382_bib101","doi-asserted-by":"crossref","DOI":"10.1111\/imm.12675","article-title":"Antigen processing and immune regulation in the response to tumours","volume":"150","author":"Reeves","year":"2017","journal-title":"Immunology"},{"key":"10.1016\/j.critrevonc.2026.105382_bib102","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/s12943-020-1144-6","article-title":"Predictive biomarkers and mechanisms underlying resistance to PD1\/PD-L1 blockade cancer immunotherapy","volume":"19","author":"Ren","year":"2020","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.critrevonc.2026.105382_bib103","doi-asserted-by":"crossref","first-page":"2021","DOI":"10.3389\/fimmu.2021.689132","article-title":"The Combination of Immune Checkpoint Blockade and Angiogenesis Inhibitors in the Treatment of Advanced Non-Small Cell Lung Cancer","volume":"12","author":"Ren","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.critrevonc.2026.105382_bib104","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1200\/JCO.23.00580","article-title":"Genomic and Immunophenotypic Landscape of Acquired Resistance to PD-(L)1 Blockade in Non\u2013Small-Cell Lung Cancer","volume":"42","author":"Ricciuti","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105382_bib105","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1007\/s10147-021-01896-x","article-title":"Outcomes of patients with non-small cell lung cancer and poor performance status treated with immune checkpoint inhibitors in the real-world setting","volume":"26","author":"Rizzo","year":"2021","journal-title":"Int. J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105382_bib106","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1080\/14737140.2022.2098718","article-title":"Immunosenescence, inflammaging, and cancer immunotherapy efficacy","volume":"22","author":"Rodriguez","year":"2022","journal-title":"Expert Rev. Anticancer Ther."},{"key":"10.1016\/j.critrevonc.2026.105382_bib107","doi-asserted-by":"crossref","first-page":"5846","DOI":"10.1158\/1538-7445.AM2025-5846","article-title":"Abstract 5846: A potent STING agonist induces endothelial PD-L1 and enhances antitumor efficacy of a novel PD-L1\/PD-L2 antibody","volume":"85","author":"Salameh","year":"2025","journal-title":"Cancer Res."},{"key":"10.1016\/j.critrevonc.2026.105382_bib108","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1007\/s00259-019-04615-x","article-title":"Baseline metabolic tumor burden on FDG PET\/CT scans predicts outcome in advanced NSCLC patients treated with immune checkpoint inhibitors","volume":"47","author":"Seban","year":"2019","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"10.1016\/j.critrevonc.2026.105382_bib109","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1038\/s41419-018-1040-9","article-title":"Sensitizing non-small cell lung cancer to BCL-xL-targeted apoptosis","volume":"9","author":"Shen","year":"2018","journal-title":"Cell Death & Dis."},{"key":"10.1016\/j.critrevonc.2026.105382_bib110","doi-asserted-by":"crossref","DOI":"10.1177\/17588359221138386","article-title":"Tumor glycolytic profiling through 18F-FDG PET\/CT predicts immune checkpoint inhibitor efficacy in advanced NSCLC","volume":"14","author":"Silva","year":"2022","journal-title":"Ther. Adv. Med. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105382_bib111","doi-asserted-by":"crossref","first-page":"SY42-02","DOI":"10.1158\/1538-7445.AM2019-SY42-02","article-title":"Abstract SY42-02: Inactivating STK11\/LKB1 genomic alterations are a major driver of primary resistance to PD-1 axis blockade in non-squamous non-small cell lung cancer","volume":"79","author":"Skoulidis","year":"2019","journal-title":"Cancer Res."},{"key":"10.1016\/j.critrevonc.2026.105382_bib112","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1038\/s41586-024-07943-7","article-title":"CTLA4 blockade abrogates KEAP1\/STK11-related resistance to PD-(L)1 inhibitors","volume":"635","author":"Skoulidis","year":"2024","journal-title":"Nature"},{"key":"10.1016\/j.critrevonc.2026.105382_bib113","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1158\/2159-8290.CD-13-0271","article-title":"Myeloid TGF-\u03b2 Responsiveness Promotes Metastases","volume":"3","author":"Souza-Fonseca-Guimaraes","year":"2013","journal-title":"Cancer Discov."},{"key":"10.1016\/j.critrevonc.2026.105382_bib114","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1158\/1538-7445.AM2024-108","article-title":"Abstract 108: Tumor-derived complement C3 is overexpressed in STK11 mutant non-small cell lung cancer and contributes to an immunosuppressive tumor microenvironment in a syngeneic mouse model","volume":"84","author":"Suzuki","year":"2024","journal-title":"Cancer Res."},{"key":"10.1016\/j.critrevonc.2026.105382_bib115","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2020.107709","article-title":"Molecular basis and therapeutic implications of CD40\/CD40L immune checkpoint","volume":"219","author":"Tang","year":"2021","journal-title":"Pharmacol. & Ther."},{"key":"10.1016\/j.critrevonc.2026.105382_bib116","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.lungcan.2019.10.012","article-title":"Gene signatures of tumor inflammation and epithelial-to-mesenchymal transition (EMT) predict responses to immune checkpoint blockade in lung cancer with high accuracy","volume":"139","author":"Thompson","year":"2020","journal-title":"Lung Cancer"},{"key":"10.1016\/j.critrevonc.2026.105382_bib117","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1002\/cam4.3590","article-title":"Clinical outcomes of immune checkpoint blockades and the underlying immune escape mechanisms in squamous and adenocarcinoma NSCLC","volume":"10","author":"Tian","year":"2021","journal-title":"Cancer Med."},{"key":"10.1016\/j.critrevonc.2026.105382_bib118","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1007\/s11864-022-01005-8","article-title":"New Immuno-oncology Targets and Resistance Mechanisms","volume":"23","author":"Tokaz","year":"2022","journal-title":"Curr. Treat. Options Oncol."},{"key":"10.1016\/j.critrevonc.2026.105382_bib119","doi-asserted-by":"crossref","DOI":"10.1093\/jncics\/pkac013","article-title":"Immunotherapy Outcomes in Individuals With Non-Small Cell Lung Cancer and Poor Performance Status","volume":"6","author":"Veluswamy","year":"2022","journal-title":"JNCI Cancer Spectr."},{"key":"10.1016\/j.critrevonc.2026.105382_bib120","doi-asserted-by":"crossref","first-page":"5657","DOI":"10.1158\/1538-7445.AM2017-5657","article-title":"Abstract 5657: Objective measurement and significance of VISTA (PD-1H) expression in non-small cell lung cancer (NSCLC)","volume":"77","author":"Villarroel-Espindola","year":"2017","journal-title":"Cancer Res."},{"key":"10.1016\/j.critrevonc.2026.105382_bib121","doi-asserted-by":"crossref","DOI":"10.1016\/j.tranon.2023.101788","article-title":"Tumor mutation burden in the prognosis and response of lung cancer patients to immune-checkpoint inhibition therapies","volume":"38","author":"Vryza","year":"2023","journal-title":"Transl. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105382_bib122","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2023.110937","article-title":"Association between pretreatment C-reactive protein level and survival in non-small cell lung cancer patients treated with immune checkpoint inhibitors: A meta-analysis","volume":"124","author":"Wang","year":"2023","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.critrevonc.2026.105382_bib123","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2020.106574","article-title":"Less immune cell infiltration and worse prognosis after immunotherapy for patients with lung adenocarcinoma who harbored STK11 mutation","volume":"84","author":"Wang","year":"2020","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.critrevonc.2026.105382_bib124","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1007\/s00259-019-04500-7","article-title":"New insight on the correlation of metabolic status on 18F-FDG PET\/CT with immune marker expression in patients with non-small cell lung cancer","volume":"47","author":"Wang","year":"2019","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"10.1016\/j.critrevonc.2026.105382_bib125","doi-asserted-by":"crossref","DOI":"10.3389\/pore.2024.1611773","article-title":"Prognostic value of lung immune prognostic index in non-small cell lung cancer patients receiving immune checkpoint inhibitors: a meta-analysis","volume":"30","author":"Wang","year":"2024","journal-title":"Pathol. & Oncol. Res."},{"key":"10.1016\/j.critrevonc.2026.105382_bib126","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbadis.2022.166521","article-title":"CXCL12 derived from CD248-expressing cancer-associated fibroblasts mediates M2-polarized macrophages to promote nonsmall cell lung cancer progression","volume":"1868","author":"Wu","year":"2022","journal-title":"Biochim. Et. Biophys. Acta (BBA) - Mol. Basis Dis."},{"key":"10.1016\/j.critrevonc.2026.105382_bib127","doi-asserted-by":"crossref","first-page":"2021","DOI":"10.3389\/fonc.2021.759015","article-title":"Metabolic Reprogramming in the Tumor Microenvironment With Immunocytes and Immune Checkpoints","volume":"11","author":"Xu","year":"2021","journal-title":"Front. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105382_bib128","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2019.108921","article-title":"Intrinsic \u03b2-catenin signaling suppresses CD8+ T-cell infiltration in colorectal cancer","volume":"115","author":"Xue","year":"2019","journal-title":"Biomed. & Pharmacother."},{"key":"10.1016\/j.critrevonc.2026.105382_bib129","doi-asserted-by":"crossref","first-page":"3406","DOI":"10.1002\/jcp.30125","article-title":"HMGB1 as a therapeutic target in disease","volume":"236","author":"Xue","year":"2020","journal-title":"J. Cell. Physiol."},{"key":"10.1016\/j.critrevonc.2026.105382_bib130","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.3389\/fonc.2020.01671","article-title":"Impact of Age on the Efficacy of Immune Checkpoint Inhibitor-Based Combination Therapy for Non-small-Cell Lung Cancer: A Systematic Review and Meta-Analysis","volume":"10","author":"Yan","year":"2020","journal-title":"Front. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105382_bib131","first-page":"52","article-title":"Role of the TME in immune checkpoint blockade resistance of non-small cell lung cancer","volume":"7","author":"Yuening","year":"2024","journal-title":"Cancer Drug Resist."},{"key":"10.1016\/j.critrevonc.2026.105382_bib132","doi-asserted-by":"crossref","DOI":"10.12659\/MSM.922576","article-title":"Effect of Comorbidity on Outcomes of Patients with Advanced Non-Small Cell Lung Cancer Undergoing Anti-PD1 Immunotherapy","volume":"26","author":"Zeng","year":"2020","journal-title":"Med. Sci. Monit."},{"key":"10.1016\/j.critrevonc.2026.105382_bib133","doi-asserted-by":"crossref","first-page":"3861","DOI":"10.1158\/1538-7445.AM2024-3861","article-title":"Abstract 3861: Associations of intragenic rearrangement burden with immune cell infiltration and response to immune checkpoint blockade in cancer","volume":"84","author":"Zhang","year":"2024","journal-title":"Cancer Res."},{"key":"10.1016\/j.critrevonc.2026.105382_bib134","article-title":"Lower respiratory tract microbiome dysbiosis impairs clinical responses to immune checkpoint blockade in advanced non-small-cell lung cancer","volume":"15","author":"Zhang","year":"2025","journal-title":"Clin. Transl. Med."},{"key":"10.1016\/j.critrevonc.2026.105382_bib135","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1158\/1538-7445.AM2020-410","article-title":"Abstract 410: Interaction between CAFs and CD8+ T in non-small cell lung cancer (NSCLC) affects prognosis and efficacy of immunotherapy","volume":"80","author":"Zheng","year":"2020","journal-title":"Cancer Res."},{"key":"10.1016\/j.critrevonc.2026.105382_bib136","first-page":"2023","article-title":"Mechanisms of drug resistance to immune checkpoint inhibitors in non-small cell lung cancer","volume":"14","author":"Zhou","year":"2023","journal-title":"Front. Immunol."},{"key":"10.1016\/j.critrevonc.2026.105382_bib137","first-page":"2022","article-title":"Mechanisms of tumor resistance to immune checkpoint blockade and combination strategies to overcome resistance","volume":"13","author":"Zhou","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.critrevonc.2026.105382_bib138","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.cytogfr.2023.11.002","article-title":"Harnessing the potential of CD40 agonism in cancer therapy","volume":"75","author":"Zhou","year":"2024","journal-title":"Cytokine Growth Factor Rev."},{"key":"10.1016\/j.critrevonc.2026.105382_bib139","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1111\/cas.16428","article-title":"Persist or resist: immune checkpoint inhibitors in EGFR-mutated NSCLC","volume":"116","author":"Zhu","year":"2025","journal-title":"Cancer Sci."},{"key":"10.1016\/j.critrevonc.2026.105382_bib140","article-title":"Metabolic-Immune Suppression Mediated by the SIRT1-CX3CL1 axis induces functional enhancement of regulatory T cells in colorectal carcinoma","volume":"12","author":"Zi","year":"2025","journal-title":"Adv. Sci."}],"container-title":["Critical Reviews in Oncology\/Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842826002696?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842826002696?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T02:45:57Z","timestamp":1787107557000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1040842826002696"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":140,"alternative-id":["S1040842826002696"],"URL":"https:\/\/doi.org\/10.1016\/j.critrevonc.2026.105382","relation":{},"ISSN":["1040-8428"],"issn-type":[{"value":"1040-8428","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Immune checkpoint inhibitor resistance in non-small cell lung cancer: An updated view through the cancer-immunity cycle","name":"articletitle","label":"Article Title"},{"value":"Critical Reviews in Oncology\/Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.critrevonc.2026.105382","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"105382"}}